Singular Genomics Systems Stock EBITDA
| OMIC Stock | USD 21.37 0.05 0.23% |
Singular Genomics Systems fundamentals help investors to digest information that contributes to Singular Genomics' financial success or failures. It also enables traders to predict the movement of Singular Stock. The fundamental analysis module provides a way to measure Singular Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Singular Genomics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -86.5 M | -82.2 M |
Singular | EBITDA |
Singular Genomics Systems Company EBITDA Analysis
Singular Genomics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Singular Genomics EBITDA | (86.5 M) |
Most of Singular Genomics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Singular Genomics Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Singular EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Singular Genomics is extremely important. It helps to project a fair market value of Singular Stock properly, considering its historical fundamentals such as EBITDA. Since Singular Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Singular Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Singular Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Singular Ebitda
Ebitda |
|
According to the company disclosure, Singular Genomics Systems reported earnings before interest,tax, depreciation and amortization of (86.5 Million). This is 109.86% lower than that of the Health Care Equipment & Supplies sector and 118.39% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.22% higher than that of the company.
Singular EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Singular Genomics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Singular Genomics could also be used in its relative valuation, which is a method of valuing Singular Genomics by comparing valuation metrics of similar companies.Singular Genomics is currently under evaluation in ebitda category among its peers.
Singular Genomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Singular Genomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Singular Genomics' managers, analysts, and investors.Environmental | Governance | Social |
Singular Genomics Institutional Holders
Institutional Holdings refers to the ownership stake in Singular Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Singular Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Singular Genomics' value.| Shares | Hightower Advisors, Llc | 2024-06-30 | 17.6 K | Tikvah Management Llc | 2024-06-30 | 10.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 726 | Tower Research Capital Llc | 2024-06-30 | 528 | Barclays Plc | 2024-06-30 | 409 | Bank Of America Corp | 2024-06-30 | 367 | Royal Bank Of Canada | 2024-06-30 | 87.0 | Rhumbline Advisers | 2024-06-30 | 55.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 36.0 | Tang Capital Management Llc | 2024-09-30 | 372 K | Deerfield Management Co | 2024-09-30 | 166.2 K |
Singular Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (30.94) % | ||||
| Current Valuation | (9.66 M) | ||||
| Shares Outstanding | 2.51 M | ||||
| Shares Owned By Insiders | 13.90 % | ||||
| Shares Owned By Institutions | 60.22 % | ||||
| Number Of Shares Shorted | 71.17 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.44 X | ||||
| Price To Sales | 19.71 X | ||||
| Revenue | 2.91 M | ||||
| Gross Profit | (24 K) | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (94.82 M) | ||||
| Cash And Equivalents | 287.98 M | ||||
| Cash Per Share | 4.05 X | ||||
| Total Debt | 75.29 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 22.98 X | ||||
| Book Value Per Share | 72.74 X | ||||
| Cash Flow From Operations | (73.65 M) | ||||
| Short Ratio | 2.30 X | ||||
| Earnings Per Share | (34.68) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 12.45 | ||||
| Number Of Employees | 255 | ||||
| Beta | 1.51 | ||||
| Market Capitalization | 53.68 M | ||||
| Total Asset | 265.47 M | ||||
| Retained Earnings | (337.6 M) | ||||
| Working Capital | 173.94 M | ||||
| Net Asset | 265.47 M |
About Singular Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Singular Genomics Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Singular Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Singular Genomics Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:Check out Singular Genomics Piotroski F Score and Singular Genomics Altman Z Score analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.